文献速递糖尿病肥胖与代谢综合征

利拉鲁肽对糖尿病前期或早期2型糖尿病肥胖受试者体重减轻、脂肪分布及β细胞功能的影响

Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes.
PubMed 文献 · Diabetes Care · 2017-09-14

62例接受二甲双胍治疗的糖尿病前期或新诊断2型糖尿病肥胖受试者随机接受利拉鲁肽1.8 mg/日或生活方式咨询,在达成约7%初始体重减重后,利拉鲁肽组内脏脂肪减少和β指数改善均显著优于生活方式组,皮下脂肪减少无差异。

要点

  • 利拉鲁肽组与生活方式组在减重约7%且HbA1c控制相当时,内脏脂肪减少利拉鲁肽组显著更多(P=0.028)。
  • β指数改善利拉鲁肽组显著优于生活方式组(P=0.021),皮下脂肪减少两组无差异(P=0.64)。
  • IGF-II血清水平仅在利拉鲁肽组显著升高(P=0.024),其升高与内脏脂肪减少和β指数增加相关。

核心结论

  • 利拉鲁肽对内脏肥胖和β细胞功能的作用可能为在糖代谢紊乱自然史早期阶段使用该药物提供依据。

研究设计与样本

  • 随机对照研究,纳入62例接受二甲双胍治疗的糖尿病前期或新诊断2型糖尿病肥胖受试者,随机分为利拉鲁肽1.8 mg/日组或生活方式咨询组。
  • 通过腹部MRI测定皮下脂肪组织和内脏脂肪组织水平,通过多时间点口服葡萄糖耐量试验评估胰岛素敏感性(Matsuda指数)和β细胞功能(β指数),并检测循环IGF-I和IGF-II水平。

主要发现

  • 两组各有20例患者达成相当的体重减轻(约为初始体重的7%),且HbA1c水平反映的血糖控制相当(P=0.60)。
  • 内脏脂肪减少利拉鲁肽组显著高于生活方式组(P=0.028),β指数改善利拉鲁肽组也显著优于生活方式组(P=0.021)。
  • 皮下脂肪减少两组间无差异(P=0.64)。
  • IGF-II血清水平仅在利拉鲁肽给药组显著升高(P=0.024),且IGF-II升高与内脏脂肪减少(ρ=-0.435,P=0.056)及β指数增加(ρ=0.55,P=0.012)相关。

临床怎么用

  • 原文结论未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Obesity is associated with an increased risk of type 2 diabetes and cardiovascular complications. The risk depends significantly on adipose tissue distribution. Liraglutide, a glucagon-like peptide 1 analog, is associated with weight loss, improved glycemic control, and reduced cardiovascular risk. We determined whether an equal degree of weight loss by liraglutide or lifestyle changes has a different impact on subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) in obese subjects with prediabetes or early type 2 diabetes. RESEARCH DESIGN AND METHODS: Sixty-two metformin-treated obese subjects with prediabetes or newly diagnosed type 2 diabetes, were randomized to liraglutide (1.8 mg/day) or lifestyle counseling. Changes in SAT and VAT levels (determined by abdominal MRI), insulin sensitivity (according to the Matsuda index), and β-cell function (β-index) were assessed during a multiple-sampling oral glucose tolerance test; and circulating levels of IGF-I and IGF-II were assessed before and after a comparable weight loss (7% of initial body weight). RESULTS: After comparable weight loss, achieved by 20 patients per arm, and superimposable glycemic control, as reflected by HbA1c level (P = 0.60), reduction in VAT was significantly higher in the liraglutide arm than in the lifestyle arm (P = 0.028), in parallel with a greater improvement in β-index (P = 0.021). No differences were observed in SAT reduction (P = 0.64). IGF-II serum levels were significantly increased (P = 0.024) only with liraglutide administration, and the increase in IGF-II levels correlated with both a decrease in VAT (ρ = -0.435, P = 0.056) and an increase in the β-index (ρ = 0.55, P = 0.012). CONCLUSIONS: Liraglutide effects on visceral obesity and β-cell function might provide a rationale for using this molecule in obese subjects in an early phase of glucose metabolism dysregulation natural history.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Santilli F, Simeone PG, Guagnano MT, et al. Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes. Diabetes Care. 2017. PMID: 28912305. doi:10.2337/dc17-0589

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。